Tagrisso has been approved in the United States for adjuvant treatment of adults patients diagnosed early enough for the tumor to be surgically removed, and who have a mutation of the EGFR gene, AstraZeneca said.
AstraZeneca's Tagrisso gets broader US approval for lung cancer
By REUTERS
09/20/2024 01:55 AM
By SHAKED SADEH
09/20/2024 01:05 AM
By AVI ASHKENAZI
09/19/2024 11:56 PM
By REUTERS
09/19/2024 11:20 PM
By REUTERS
09/19/2024 10:42 PM
By REUTERS
09/19/2024 10:36 PM
By REUTERS
09/19/2024 10:23 PM
By REUTERS
09/19/2024 08:11 PM
By REUTERS
09/19/2024 07:51 PM